Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGXNASDAQ:FRESNYSE:LHNASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$178.95-1.7%$173.21$135.47▼$182.38$19.98B0.491.19 million shs861,486 shsFRESFresh2 Group$0.85$0.96$0.73▼$3.78$765K1.329,081 shsN/ALHLaboratory Co. of America$259.36-1.7%$241.51$198.96▼$264.03$21.71B0.81715,476 shs659,739 shsNTRANatera$167.55-0.4%$155.28$92.14▼$183.00$22.88B1.741.54 million shs899,329 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.12%+3.50%+2.35%+5.72%+32.07%FRESFresh2 Group0.00%0.00%0.00%0.00%-76.05%LHLaboratory Co. of America+1.19%+3.21%+5.75%+10.15%+32.05%NTRANatera+1.76%+2.47%+10.26%+15.02%+52.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDGXQuest Diagnostics4.89 of 5 stars2.34.04.24.73.02.52.5FRESFresh2 GroupN/AN/AN/AN/AN/AN/AN/AN/ALHLaboratory Co. of America4.4093 of 5 stars2.43.02.54.22.82.51.3NTRANatera1.8622 of 5 stars2.52.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.69Moderate Buy$185.733.79% UpsideFRESFresh2 Group 4.00Strong BuyN/AN/ALHLaboratory Co. of America 2.86Moderate Buy$274.005.65% UpsideNTRANatera 3.00Buy$184.6310.19% UpsideCurrent Analyst Ratings BreakdownLatest FRES, LH, NTRA, and DGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025LHLaboratory Co. of AmericaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$270.00 ➝ $283.005/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/12/2025LHLaboratory Co. of AmericaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$274.00 ➝ $290.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/6/2025LHLaboratory Co. of AmericaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$260.00 ➝ $280.005/6/2025DGXQuest DiagnosticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$180.00 ➝ $190.004/30/2025LHLaboratory Co. of AmericaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$240.00 ➝ $250.004/30/2025LHLaboratory Co. of AmericaRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$253.00 ➝ $267.004/28/2025DGXQuest DiagnosticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$180.00 ➝ $200.004/23/2025DGXQuest DiagnosticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$182.00 ➝ $190.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$10.16B1.97$13.96 per share12.82$61.04 per share2.93FRESFresh2 Group$1.75M0.44N/AN/AN/A∞LHLaboratory Co. of America$13.18B1.65$23.39 per share11.09$96.27 per share2.69NTRANatera$1.83B12.50N/AN/A$6.37 per share26.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$7.9123.2717.062.168.80%15.07%6.72%7/22/2025 (Estimated)FRESFresh2 Group-$14.77MN/A0.00∞N/AN/AN/AN/AN/ALHLaboratory Co. of America$746M$8.6529.4114.791.715.73%15.29%7.01%7/30/2025 (Estimated)NTRANatera-$434.80M-$1.47N/AN/AN/A-14.01%-26.23%-14.27%8/14/2025 (Estimated)Latest FRES, LH, NTRA, and DGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/29/2025Q1 2025LHLaboratory Co. of America$3.73$3.84+$0.11$2.52$3.41 billion$3.35 billion4/22/2025Q1 2025DGXQuest Diagnostics$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.79%N/A40.46%14 YearsFRESFresh2 GroupN/AN/AN/AN/AN/ALHLaboratory Co. of America$2.881.11%N/A33.29%N/ANTRANateraN/AN/AN/AN/AN/ALatest FRES, LH, NTRA, and DGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/14/2025DGXQuest Diagnosticsquarterly$0.801.86%7/7/20257/7/20257/21/20254/10/2025LHLaboratory Co. of Americaquarterly$0.721.25%5/29/20256/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.821.101.02FRESFresh2 GroupN/AN/AN/ALHLaboratory Co. of America0.671.441.30NTRANatera0.334.394.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%FRESFresh2 Group0.45%LHLaboratory Co. of America95.94%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics8.16%FRESFresh2 Group26.22%LHLaboratory Co. of America0.84%NTRANatera7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics49,000111.64 million110.73 millionOptionableFRESFresh2 Group75900,000663,000Not OptionableLHLaboratory Co. of America75,50083.70 million82.93 millionOptionableNTRANatera3,020136.55 million121.99 millionOptionableFRES, LH, NTRA, and DGX HeadlinesRecent News About These CompaniesPrecision Wealth Strategies LLC Makes New $803,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 16 at 7:34 AM | marketbeat.comElevation Point Wealth Partners LLC Sells 1,616 Shares of Natera, Inc. (NASDAQ:NTRA)June 16 at 4:06 AM | marketbeat.comHere's How Much You Would Have Made Owning Natera Stock In The Last 10 YearsJune 13, 2025 | benzinga.comHarbor Capital Advisors Inc. Sells 4,030 Shares of Natera, Inc. (NASDAQ:NTRA)June 13, 2025 | marketbeat.comGail Boxer Marcus Sells 4,000 Shares of Natera, Inc. (NASDAQ:NTRA) StockJune 12, 2025 | insidertrades.comNet Worth Advisory Group Takes Position in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $60.92 Million Position in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comHandelsbanken Fonder AB Boosts Stock Position in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comWedmont Private Capital Makes New $223,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 12, 2025 | marketbeat.comInsider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 4,000 Shares of StockJune 11, 2025 | marketbeat.comDuquesne Family Office LLC Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)June 11, 2025 | marketbeat.comRockingstone Advisors LLC Has $2.84 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)June 11, 2025 | marketbeat.comPallas Capital Advisors LLC Acquires 2,713 Shares of Natera, Inc. (NASDAQ:NTRA)June 11, 2025 | marketbeat.comNTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance IncreaseJune 10, 2025 | msn.comSG Americas Securities LLC Has $56.27 Million Stake in Natera, Inc. (NASDAQ:NTRA)June 10, 2025 | marketbeat.comLake Hills Wealth Management LLC Makes New $440,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 7, 2025 | marketbeat.comMerit Financial Group LLC Has $1.33 Million Holdings in Natera, Inc. (NASDAQ:NTRA)June 7, 2025 | marketbeat.comRhumbline Advisers Has $21.69 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)June 7, 2025 | marketbeat.comE. Ohman J or Asset Management AB Sells 5,200 Shares of Natera, Inc. (NASDAQ:NTRA)June 6, 2025 | marketbeat.comGAMMA Investing LLC Buys 119,275 Shares of Natera, Inc. (NASDAQ:NTRA)June 6, 2025 | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 SharesJune 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?BigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?Astronics Corporation: Up 100% YTD in May and Heading HigherBy Thomas Hughes | May 28, 2025View Astronics Corporation: Up 100% YTD in May and Heading HigherFRES, LH, NTRA, and DGX Company DescriptionsQuest Diagnostics NYSE:DGX$178.95 -3.12 (-1.71%) Closing price 03:59 PM EasternExtended Trading$178.92 -0.02 (-0.01%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Fresh2 Group NASDAQ:FRESFresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.Laboratory Co. of America NYSE:LH$259.36 -4.60 (-1.74%) Closing price 03:59 PM EasternExtended Trading$250.08 -9.27 (-3.58%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.Natera NASDAQ:NTRA$167.55 -0.70 (-0.42%) Closing price 04:00 PM EasternExtended Trading$166.99 -0.56 (-0.33%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
